Summary The pNR-2/pS2 protein is regulated by oestrogens in breast cancer cell lines. This report describes a systematic survey of pNR-2/pS2 expression in a number of common epithelial tumours. Expression was evaluated immunohistochemically in an archival series using antisera raised against the C-terminus of the pNR-2/pS2 protein. Expression of pNR-2/pS2 by malignant epithelial tumours was widespread. Intense immunohistochemical staining was found in tumour cells in a proportion of pancreatic (6/8), large intestinal (7/12), gastric (9/16) and endometrial (4/12) carcinomas. Positive staining for the pNR-2/pS2 protein was also found in both benign and malignant ovarian epithelial tumours and was very significantly associated with mucinous differentiation (P <0.00001). Small numbers of carcinomas of bladder (2/10) and prostate (2/7) showed less intense staining and single examples of cervical carcinoma (1/7) and lung carcinoma (1/19) stained positively. None of the renal carcinomas (0/16) examined stained positively. Positive staining showed no correlation with gender. Although there are reports of oestrogen receptor expression in most of the tumour types considered, the possibility of other regulatory influences must also be considered. The pNR-2/pS2 protein may well have a more general role in human epithelial neoplasia than hitherto realised.
The pNR-2/pS2 messenger RNA was originally detected in oestrogen-responsive breast cancer cell lines by virtue of its regulation by oestrogen (Masiakowski et al., 1982; Prud'homme et al., 1985; May & Westley, 1986) . The pNR-2/pS2 mRNA encodes a small, cysteine-rich protein of 84 amino acids (Jakowlew et al., 1984) which is secreted from breast cancer cells (Nunez et al., 1987) as a mature 60 amino acid protein (Rio et al., 1988a) . Oestrogen regulation of the pNR-2/pS2 gene is conferred by a short enhancer region in the 5' flanking region of the gene . The function of the pNR-2/pS2 protein is unknown but it. shows some structural similarity to small peptide growth factors such as insulin-like growth factor I and a high degree of homology to porcine pancreatic spasmolytic polypeptide (Rio et al., 1988b) . In breast cancer the pNR-2/pS2 mRNA and protein are expressed predominantly in oestrogen receptor positive tumours Henry et al., 1990; Henry et al., 1991) and high levels of the protein are predictive of favourable prognosis (Foekens et al., 1990) . Expression of pNR-2/pS2 is also predictive of a favourable response to endocrine therapy in advanced breast cancer .
In normal tissue, the pNR-2/pS2 protein is expressed in gastric mucosa (Rio et al., 1988a) , small intestinal mucosa and in normal breast epithelium (Piggott et al., 1991) . Amongst malignant epithelial tumours, the pNR-2/pS2 protein has been detected in gastric carcinomas and gynaecological cancers (Wysocki et al., 1990) .
To date there has been no systematic evaluation of the expression of this intriguing protein in primary epithelial tumours arising in different organs. We have recently raised a rabbit polyclonal antiserum to a synthetic peptide derived from the C-terminal region of the pNR-2/pS2 protein (Piggott et al., 1991) . This antiserum is effective on conventionally fixed, paraffin embedded, histological material. We now report an immunohistochemical survey of pNR-2/pS2 expression in common epithelial tumours.
Materials and methods
Surgically resected tumours and tumour biopsies were fixed overnight in phosphate-buffered 4% formalin and representative blocks selected: the majority of blocks were post-fixed in formal sublimate (saturated aqueous mercuric chloride and 40% formaldehyde, 9: 1). Fixed blocks were dehydrated through increasing concentrations of ethanol and then soaked in xylene prior to embedding in paraffin wax. Three ,sm sections were cut onto poly-l-lysine coated slides for immunohistochemical study.
In the first instance, sections were stained immunohistochemically using a diaminobenzidine peroxidase: antiperoxidase technique (Sternberger et al., 1970) as described previously (Piggott et al., 1991) . The primary-antiserum was a rabbit polyclonal raised against a synthetic 31 amino acid peptide corresponding to the C-terminus of the pNR-2/pS2 protein (Piggott et al., 1991) . Sections were treated with 0.1% trypsin prior to application of the primary antiserum (diluted 1/200 in normal swine serum (NSS)). Negative controls were performed for each case and comprised omission of either the primary antiserum or of both the primary and the secondary antisera. Sections of normal gastric body mucosa served as a positive control for each run of immunohistochemical staining.
A streptavidin:biotin peroxidase immunohistochemical technique (Wood & Warnke, 1981) The specific detection of pNR-2/pS2 expression was confirmed by the absence of staining when the antisera was preabsorbed with the synthetic peptide that had been used as the immunogen. There was considerable variation in the proportion of tumour cells that expressed pNR-2/pS2 and in the intensity of staining.
The highest incidence of positive staining was found in pancreatic carcinomas (75%; Table I ). Positive pNR-2/pS2 immunohistochemical staining was cytoplasmic and showed a tendency to perinuclear accentuation (Figure 1 ). Pancreatic tumours also contained some of most intensely stained cells and some of them contained high proportions of positively stained cells (Table I) . Positive cytoplasmic staining was found in tumour cells scattered throughout the neoplastic glandular elements: background staining was minimal (Figure 1 ).
Intense cytoplasmic staining of tumour cells was also found in appreciable numbers of carcinomas of large bowel (58%), stomach (56%) and endometrium (33%; Table I ). In all of the positive examples, tumour cell staining was again cytoplasmic with a tendency to perinuclear accentuation. In positively stained large bowel carcinomas both diffuse and focal patterns of staining were observed (Figure 2 expression has since been reported in gastric and gynaecological cancers (Wysocki et al., 1990 ). This report is the first survey of the extent of the pNR-2/pS2 expression in common human epithelial tumours. We have found that pNR-2/pS2 expression is a widespread phenomenon: of the tumours examined only renal adenocarcinomas did not show any expression at all (Table I) . Convincing pNR-2/pS2 immunohistochemical staining was found in appreciable numbers of carcinomas of pancreas, large bowel, stomach, ovary and endometrium: weaker staining was found in a proportion of prostatic and bladder carcinomas. Single examples of both cervical and lung carcinomas stained positively. We detected a lower proportion of pNR-2/pS2 positive gastric carcinomas than Luqmani et al. (1989) but as both studies included only relatively small numbers of gastric carcinomas the proportions may be considered broadly comparable. The proportion of ovarian and endometrial carcinomas in which pNR-2/pS2 was detectable immunohistochemically is however considerably higher than that reported by Wysocki et al. (1990) who studied expression of pNR-2/pS2 mRNA in Northern blots of total cellular RNA extracts: it is possible that the significant proportion of stromal cells in these tumours militates against detection of a mRNA expressed solely in a proportion of the malignant epithelial cells. For the purposes of comparison, the results obtained with a large series (171) of primary breast tumours are shown in Table I . While the numbers of tumours in each group in the present series are smaller, it is interesting that pNR-2/pS2 is expressed in a similar proportion of breast, pancreatic, large bowel and gastric tumours. In addition, the mean proportion of cells in which pNR-2/pS2 expression was detected in the breast tumours is lower than in some of the other tumour types. Thus pNR-2/pS2 expression is at least as prevalent in some other epithelial tumours as it is in breast cancer. Malignant ovarian tumours of surface epithelium form a heterogeneous group and the current series was chosen to represent the more common tumours which show either serous or mucinous differentiation. Immunohistochemical staining for the pNR-2/pS2 protein was found to associate very significantly with mucinous diffentiation (Table II) : a similar association with mucinous differentiation has been observed by Wysocki et al. (1990) but they did not have sufficient numbers of pNR-2/pS2 positive tumours for statistical analysis. We have investigated this association further in a series of benign serous and mucinous cystadenomas of ovary and found a similar and significant association. Although the association of pNR-2/pS2 expression with mucinous differentition is not absolute, antibodies to pNR-2/ pS2 may be useful reagents for determining differentiation in diagnostically problematic ovarian tumours. The divergent differentiation found in ovarian epithelial tumours is thought to result from the capacity of ovarian surface epithelium to differentiate into each of the types of Mullerian epithelium, with mucinous tumours differentiating along the line of endocervical epithelium. A series of normal endocervices in ten hysterectomy specimens was also stained immunohistochemically with the pNR-2/pS2 antiserum but there was no evidence of pNR-2/pS2 expression (data not shown). It is however interesting that the only cervical carcinoma to stain positively was the only adenocarcinoma of endocervix in a group otherwise composed to squamous carcinomas. Expression of pNR-2/pS2 in epithelial tumours of Mullerian origin may occur as part of neoplastic progression.
We have detected pNR-2/pS2 expression in normal breast, stomach, small intestine and prostate in a previous study (Piggott et al., 1991) and in apparently normal large bowel epithelium adjacent to a colonic tumour in the present study. Wright et al. (1991) have described pNR-2/pS2 expression in intestinal mucosa adjacent to areas of mucosal damage and it is possible that a similar phenomenon occurs in normal colorectal epithelium adjacent to some tumours. Clearly pNR-2/pS2 expression by human malignant epithelial tumours is not restricted to those tissues in which the protein is normally expressed. The factors that control the ectopic expression of this protein are currently unknown. In human breast cancer at least, expression of the pNR-2/ pS2 mRNA or protein is almost entirely confined to a proportion of breast cancers that express oestrogen receptor Skilton et al., 1989; Henry et al., 1990; Foekens et al., 1990) . This implies that oestrogens regulate the expression of the pNR-2/pS2 gene in breast cancer cells. The question then arises, is this gene regulated by oestrogens acting through the oestrogen receptor in the other malignant tumours in which it is expressed? Oestrogen receptor has been detected in a proportion of ovarian epithelial tumours (Schwartz et al., 1982; Bizzi et al., 1988) and endometrial carcinomas (Palmer et al., 1988) . More surprisingly, oestrogen receptor has also been detected in gastric carcinomas (Sica et al., 1984; Tokunga et al., 1986) , colorectal carcinomas (McClendon et al., 1977; Sica et al., 1984) and pancreatic carcinomas (Greenway et al., 1981) . Furthermore, a favourable response to antioestrogen therapy and other endocrine therapies has been recorded in pancreatic carcinoma (reviewed by Greenway, 1987) . Expression of pNR-2/ pS2 in normal gastric mucosa and gastric carcinomas has however been reported to be independent of oestrogen receptor expression (Rio et al., 1988a; Luqmani et al., 1989) and Wysocki et al. (1990) only observed a weak correlation between oestrogen receptor mRNA and pNR-2/pS2 mRNA expression in ovarian epithelial tumours. Unfortunately, as the tumours in this study are an archival series from which only formalin fixed, paraffin embedded material is available and as receptor assays were not performed at the time of resection we are unable to correlate oestrogen receptor and pNR-2/pS2 expression. However in the current series, gender (and consequent gender dependent differences in sex steroid levels) did not show any relationship to the proportion of tumours expressing pNR-2/pS2 ( Table I) . As the majority of tumours from women were from elderly, postmenopausal women analysis of the effect of menopausal status was not possible.
Other factors may regulate pNR-2/pS2 gene expression in these tumours. The pNR-2/pS2 gene has a complex upstream promoter region that contains enhancer elements responsive to epidermal growth factor, the c-Ha-ras oncoprotein, the c-jun protein and a tumour promoter . Co-expression of epidermal growth factor and pNR-2/pS2 has been described in intact mucosa at the edge of intestinal ulcers and it has been suggested that in this instance pNR-2/ pS2 expression is controlled by epidermal growth factor (Wright et al., 1991) . It is also possible that pNR-2/pS2 is expressed constitutively in a proportion of tumours.
The function of the pNR-2/pS2 protein however remains enigmatic. If the pNR-2/pS2 protein is indeed a growth factor it is possible that it may stimulate tumour growth by autocrine means. The biological and prognostic significance of pNR-2/pS2 expression, particularly in non-mammary tumours, remains to be determined. The frequent expression of this protein in diverse human malignancies suggests that pNR-2/pS2 could have a more general role in human neoplasia than hitherto realised. 
